Biotech stocks generally refer to stocks of companies that are mainly engaged in the development and commercialization of biotechnology-related products, services or research. With the aging of the global population and the increasing attention to health issues, the demand in the field of biotechnology has also increased accordingly. The advancement of science and technology complements the development of the biotechnology industry. In today's society where people's needs are constantly increasing, the biotechnology concept sector is undoubtedly an important investment direction.

Longeveron

Founded in 2021, Longeveron Inc is a young, dynamic and fast-growing biotechnology company. He is committed to developing regenerative drugs to meet unmet medical needs in aging-related and life-threatening special diseases. The company's R&D products treat diseases such as hypoplastic left heart syndrome (HLHS) and Alzheimer's disease (AD).

On June 14, the company's stock rose all the way, with an increase of 19.43% and a turnover of US$9.7 million. The company's stock price has fallen continuously in the past three months, and the recent rise is extraordinary.

source：uSMART SG

Disc Medicine

Disc Medicine Inc is a clinical research-focused biopharmaceutical company dedicated to the treatment of blood diseases. The company is building a series of innovative therapeutic candidates that affect basic pathways of red blood cell biology. The company has integrated a series of clinical and preclinical product candidates designed to alter basic biological pathways related to red blood cell formation and function, especially heme biosynthesis and iron homeostasis.

On June 17, the company's stock price rose as much as 18%, reaching $46, and the company's current total market value is $1.117 billion. On the same day, Wedbush raised the company's target price from $43 to $57.

source：uSMART SG

UroGen Pharma

UroGen Pharma is a biotech company focused on the treatment of specialty cancers such as urothelial carcinoma. The company developed its own RTGel reverse thermal gel to enhance the therapeutic effect of existing drugs by achieving sustained release. Their flagship product Jelmyto (mitomycin) for renal pelvic solution, and the investigational candidate UGN-102 (mitomycin) for intravesical solution, target non-surgical tumor ablation of non-muscle invasive urothelial carcinoma.

Surprisingly, UroGen Pharma's stock price has risen by nearly 60% in the past year. Multiple analysts maintained a buy rating on UroGen Pharma and raised the company's target price. The company's stock has strengthened investors' confidence with its amazing performance.

source：uSMART SG

Ocular Therapeutix

Oural Therapeutix Inc is specialized in the treatment of ocular diseases and conditions. The company utilizes its proprietary hydrogel platform technology to deliver therapeutic agents to the eye. Its product line includes ophthalmic drugs designed to overcome the limitations of current eye drop-based therapies for ocular diseases and conditions. Its pipeline products include Dextenza, OTX-TIC, OTX-TKI, and OTX-IVT.

On June 13, the company reported its clinical development progress, followed by a 13% increase in its stock price on Friday. Currently, the company's stock price has risen by more than 14%.

source：uSMART SG

Follow us

Find us on Twitter, Instagram, YouTube, and TikTok for frequent updates on all things investing.

Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！

Important Notice and Disclaimer:

This document is prepared by uSMART. This document is not intended for or directed at persons under local laws or regulations that prohibit the distribution or publication of this document. This document is provided to the recipient only, and the information, materials, or analytical tools contained herein are provided to the recipient for informational and reference purposes only. This document should not be construed in any jurisdiction as constituting an offer, solicitation, recommendation, inducement, endorsement, opinion, or guarantee to purchase, sell, or trade any securities, financial products, or instruments or to engage in any investment or any transaction of any kind, nor is there any intention to solicit or invite the purchase or sale of any securities.

Investment involves risks. Before making investment decisions, the recipient should carefully read relevant offering documents to obtain further information, including risk factors. Past performance data does not imply similar future performance. Investments in the asset categories mentioned in this document may not be suitable for all recipients. This document does not consider the individual objectives, financial situation, or needs of any specific person who may access this document. Before engaging in any transactions, the recipient should take reasonable actions based on personal objectives and circumstances to ensure a clear understanding of the transaction and independently evaluate the suitability of the transaction, including assessing the potential risks and returns of the transaction, and if necessary, seek independent professional advice. The information and opinions contained in this document reflect the judgment of uSMART as of its publication date, and no further notice will be given in the event of changes. Neither we or our respective directors, officers or employees will be responsible for any losses or damages which any person may suffer or incur as a result of relying upon anything stated or omitted from this article.

The value of these securities and the income from them may fall or rise. Your investment is subject to investment risk, including loss of income and capital invested. Past performance figures as well as any projection or forecast used in this article is not indicative of its future performance.

This advertisement has not been reviewed by the Monetary Authority of Singapore.